J. Avouac, F. Amrouche, C. Meune, G. Rey, A. Kahan et al., Mortality profile of patients with rheumatoid arthritis in France and its change in 10 years, Semin Arthritis Rheum, vol.46, pp.537-580, 2017.

O. Distler, K. B. Highland, M. Gahlemann, A. Azuma, A. Fischer et al., Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease, N Engl J Med, vol.380, pp.2518-2546, 2019.

K. R. Flaherty, A. U. Wells, V. Cottin, A. Devaraj, S. Walsh et al., Nintedanib in Progressive Fibrosing Interstitial Lung Diseases, N Engl J Med, vol.381, pp.1718-1727, 2019.

M. Elhai, A. M. Hoffmann-vold, J. Avouac, S. Pezet, A. Cauvet et al., Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis & rheumatology, vol.71, pp.972-82, 2019.

E. R. Volkmann, D. P. Tashkin, M. Kuwana, N. Li, M. D. Roth et al., Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18, Arthritis & rheumatology, vol.71, pp.2059-67, 2019.

A. M. Hoffmann-vold, A. H. Tennoe, T. Garen, O. Midtvedt, A. Abraityte et al., High Level of Chemokine CCL18 Is Associated With Pulmonary Function Deterioration, Lung Fibrosis Progression, and Reduced Survival in Systemic Sclerosis, Chest, vol.150, pp.299-306, 2016.

F. C. Arnett, S. M. Edworthy, D. A. Bloch, D. J. Mcshane, J. F. Fries et al., The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, Arthritis Rheum, vol.31, pp.315-339, 1988.

D. Aletaha, T. Neogi, A. J. Silman, J. Funovits, D. T. Felson et al., Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative, Arthritis Rheum, vol.62, pp.2569-81, 2010.
URL : https://hal.archives-ouvertes.fr/hal-01557559

P. A. Juge, J. S. Lee, E. Ebstein, H. Furukawa, E. Dobrinskikh et al., MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease, N Engl J Med, vol.379, pp.2209-2228, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02191891

N. S. Goh, S. R. Desai, S. Veeraraghavan, D. M. Hansell, S. J. Copley et al., Interstitial lung disease in systemic sclerosis: a simple staging system, Am J Respir Crit Care Med, vol.177, pp.1248-54, 2008.

W. Wu, S. Jordan, M. O. Becker, R. Dobrota, B. Maurer et al., Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model, Ann Rheum Dis, vol.77, pp.1326-1358, 2018.

M. Elhai, J. Avouac, and Y. Allanore, Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand? Semin Arthritis Rheum

, , pp.30006-30014

A. Prasse, D. V. Pechkovsky, G. B. Toews, W. Jungraithmayr, F. Kollert et al., A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18, Am J Respir Crit Care Med, vol.173, pp.781-92, 2006.

T. Oyama, N. Kohno, A. Yokoyama, Y. Hirasawa, K. Hiwada et al., Detection of interstitial pneumonitis in patients with rheumatoid arthritis by measuring circulating levels of KL-6, a human MUC1 mucin, Lung, vol.175, pp.379-85, 1997.

J. S. Lee, E. Y. Lee, Y. J. Ha, E. H. Kang, Y. J. Lee et al., Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease, Arthritis Res Ther, vol.21, p.30764869, 2019.

P. Kiely, A. D. Busby, E. Nikiphorou, K. Sullivan, D. A. Walsh et al., Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts, BMJ open, vol.9, 2019.

F. Kinoshita, H. Hamano, H. Harada, T. Kinoshita, T. Igishi et al., Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT, Respir Med, vol.98, pp.1131-1138, 2004.

H. C. Kim, K. H. Choi, J. Jacob, and J. W. Song, Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease, PLoS One, vol.15, 2020.